NLRP3 and gout: Colchicine has been shown to have several mechanisms of action in the treatment of gout, including inhibiting the activation of the NLRP3 inflammasome, blocking the release of IL-1β (Cronstein and Terkeltaub, 2006; Nuki, 2008; Dalbeth et al., 2014).